Orchestra BioMed Holdings (OBIO) Income from Non-Controlling Interests (2021)

Orchestra BioMed Holdings' (OBIO) quarterly Income from Non-Controlling Interests came in at -$92329.0 in Q2 2021.

Orchestra BioMed Holdings (OBIO) Income from Non-Controlling Interests (2021) Analysis & Trends

Orchestra BioMed Holdings (OBIO) has 1 years of Income from Non-Controlling Interests data on file, last reported at -$92329.0 in Q2 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn -
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn -
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 Orchestra BioMed Holdings 235.83 Mn 141.43 Mn 78,000.00 -

Historic Data

Download Data
DateValue
Jun 30, 2021 -92,329.00